CytomX Therapeutics
CytomX Therapeutics, founded in 2008 and based in South San Francisco, develops Probody therapeutics aimed at enhancing cancer treatment by localizing effects to tumors and minimizing impact on healthy tissues.
Overview of CytomX Therapeutics
CytomX Therapeutics, founded in 2008 and headquartered in South San Francisco, California, focuses on developing Probody therapeutics. These therapeutics are designed to target and treat cancer by exploiting the unique conditions of the tumor microenvironment. The company's innovative approach aims to localize treatments within tumors, thereby limiting their activity in healthy tissue.
CytomX Therapeutics Probody Technology
CytomX Therapeutics specializes in Probody therapeutics, a novel class of drugs engineered to be active only within the tumor microenvironment. This design aims to enhance the efficacy of cancer treatment while minimizing adverse effects on healthy tissues. By leveraging this selective activation, the company seeks to deliver more effective and safer oncology therapies.
Clinical-Stage Pipeline at CytomX Therapeutics
CytomX Therapeutics boasts a broad, clinical-stage pipeline comprising multiple Probody programs. These programs are currently in the clinical phase, striving to revolutionize cancer treatment through targeted and localized therapeutic interventions. The pipeline's focus on clinical-stage development highlights the company's commitment to bringing innovative treatments to market.
Strategic Collaborations of CytomX Therapeutics
CytomX Therapeutics has entered into strategic collaborations with several leading oncology entities. These partnerships include notable names such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. These collaborations aim to leverage collective expertise and resources to advance the development of Probody therapeutics and facilitate innovative cancer treatment solutions.
Founding and Headquarter Details of CytomX Therapeutics
Founded in 2008, CytomX Therapeutics is headquartered in South San Francisco, California. The company's establishment marks a significant step towards developing targeted cancer therapies, with its headquarters serving as a central hub for research, development, and collaboration.
